Table 2.
Ionizing radiation-induced foci (IRIF)/cell relative to 6 Gy IR plus dimethyl sulfoxide (DMSO) control at 24-hour time point for drugs classified as antineoplastics in the approved oncology drugs set screen at two concentrations
| DNA-damaging agent | Mechanism of action | IRIF/cell relative to IR + DMSO
|
|
|---|---|---|---|
| 50 μM | 6.25 μM | ||
| Temozolomide | Base alkylation | 2.57 | 1.04 |
| Pipobroman | Base alkylation | 2.55 | 1.25 |
| Thiotepa | Base alkylation | 2.43 | 1.50 |
| Chlorambucil | Base alkylation | 2.30 | 1.30 |
| Benzophenanthridine | Topoisomerase II inhibitor | 2.36 | 0.60 |
| Teniposide | Topoisomerase II inhibitor | 1.66 | 0.93 |
| Etoposide | Topoisomerase II inhibitor | 0.41 | 1.95 |
| Mitoxantrone | Topoisomerase II inhibitor | Toxic | 0.20 |
| Cisplatin | Intrastrand crosslinker | 2.12 | 0.93 |
| Oxaliplatin | Intrastrand crosslinker | 1.93 | 1.08 |
| Carboplatin | Intrastrand crosslinker | 1.59 | 1.26 |
| Bleomycin | Interstrand crosslinker | 3.31 | 1.71 |
| Thioguanine | Purine synthesis inhibitor | 3.39 | 1.60 |
| Pentostatin | Adenosine deaminase inhibitor | 1.57 | 0.63 |
| Cladribine | Adenosine deaminase inhibitor | 1.65 | 1.42 |
| Deoxyadenosine | Adenosine deaminase inhibitor | 1.75 | 1.17 |
| Doxorubicin | Alkylator | 1.12 | 2.12 |
| Valrubicin | Alkylator | 1.88 | 1.46 |
| Cytaribine | DNA polymerase inhibitor | 2.42 | 1.92 |
| Docetaxel | Tubulin stabilizer | 1.66 | 1.38 |
| Arsenic trioxide | Thioredoxin reductase inhibitor | 3.42 | 1.54 |